Marisa Wexler, MS,  senior science writer—

Researchers recently described the case of a young woman diagnosed with Lambert-Eaton Myasthenic syndrome (LEMS) together with another very rare immune disorder called autoimmune enteropathy. The report, “A Rare Case of Autoimmune Enteropathy Associated With Lambert-Eaton Myasthenic Syndrome and a Literature Review,” was published in Cureus. Normally, the…

Catalyst Pharmaceuticals and Lupin have settled a legal dispute related to Lupin’s generic version of Firdapse (amifampridine) — an approved brand-name treatment for Lambert-Eaton myasthenic syndrome (LEMS). Under the terms of the new deal, Lupin will not market its generic therapy in the U.S. prior to…

The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of more than 30 cancer centers across the U.S., has now included recommendations for testing for and managing Lambert-Eaton myasthenic syndrome (LEMS) in its updated guidelines for managing small cell lung cancer. While LEMS — an immune condition marked by…

Some people with Lambert–Eaton myasthenic syndrome (LEMS) experience a phenomenon called postexercise facilitation of reflexes, where normal reflexes are initially absent but then briefly return after a muscle is flexed. The case of a man who was diagnosed with LEMS after doctors noted postexercise facilitation of reflexes was…

Firdapse (amifampridine), an approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS), is now available to people in Japan with the rare autoimmune disease. The therapy, available in the form of 10 mg tablets, was launched by Dydo Pharma. Dydo is responsible for the development and commercialization…

Anti-CD19 CAR T-cell therapy was found to be effective in treating a 54-year-old man with Lambert-Eaton myasthenic syndrome (LEMS) who wasn’t responding to other immune-suppressing and symptomatic treatments, according to a case report from researchers in Germany. The team’s observations suggest that this type of cell therapy may be…

Firdapse (amifampridine) can help ease symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in patients who don’t have an underlying cancer and its efficacy is consistent regardless of how long a delay there is before it’s started. That’s according to a study, “Safety, efficacy and steroid-sparing…

The rare case of a man with lung cancer complicated by two co-occurring cancer-associated syndromes — Lambert-Eaton myasthenic syndrome (LEMS) and syndrome of inappropriate antidiuretic hormone secretion (SIADH) — was described in a recent report. According to its scientists, only four other documented reports of LEMS and SIADH developing…

DyDo Pharma is seeking approval of Firdapse (amifampridine) to treat Lambert-Eaton myasthenic syndrome (LEMS) in Japan. A decision from Japan’s Pharmaceuticals and Medical Devices Agency is expected in September. DyDo’s application was submitted in collaboration with Catalyst Pharmaceuticals, which developed Firdapse. DyDo is leading the development…

The rare case of a man with Lambert-Eaton myasthenia syndrome (LEMS) that co-occurred with non-Hodgkin lymphoma, a type of immune cell cancer, was described in a recent report. “In this case report, we present the case of a 57-year-old male diagnosed with non-Hodgkin’s lymphoma (NHL) who developed LEMS, an…